Scan Science and Technology
Contact Leading Edge Experts & Companies
Asthma Pathophysiology
The Experts below are selected from a list of 5700 Experts worldwide ranked by ideXlab platform
Hans Bisgaard – One of the best experts on this subject based on the ideXlab platform.
-
Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. Discussion
The Journal of Allergy and Clinical Immunology, 2003Co-Authors: Anthony P Sampson, Redwan Moqbel, Hans Bisgaard, Emilio Pizzichini, Mark C. Liu, Stephen P. PetersAbstract:The understanding that Asthma Pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highly invasive (bronchial biopsy, bronchoalveolar lavage), moderately direct, and less invasive (indirect sputum, exhaled air, breath condensate) or indirect and least invasive (blood, urine). Several studies described in this review have implicated the cysteinyl leukotrienes (CysLTs) as inflammatory mediators in a wide range of diseases, implying that their biological activities reach far beyond acute bronchoconstriction, the activity traditionally ascribed to them. The validity of examining sputum for biomarkers has improved the understanding of Asthma Pathophysiology, optimization of Asthma treatment and management, and investigation of the relation between CysLTs and airway inflammation in Asthma. Nitric oxide is also a surrogate marker of Asthma and reflects airway inflammation. The anti-inflammatory effects of the leukotriene receptor antagonists and the markers of their activity continue to grow.
-
Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation.
The Journal of allergy and clinical immunology, 2003Co-Authors: Anthony P Sampson, Emilio Pizzichini, Hans BisgaardAbstract:The understanding that Asthma Pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highly invasive (bronchial biopsy, bronchoalveolar lavage), moderately direct, and less invasive (indirect sputum, exhaled air, breath condensate) or indirect and least invasive (blood, urine). Several studies described in this review have implicated the cysteinyl leukotrienes (CysLTs) as inflammatory mediators in a wide range of diseases, implying that their biological activities reach far beyond acute bronchoconstriction, the activity traditionally ascribed to them. The validity of examining sputum for “biomarkers” has improved the understanding of Asthma Pathophysiology, optimization of Asthma treatment and management, and investigation of the relation between CysLTs and airway inflammation in Asthma. Nitric oxide is also a surrogate marker of Asthma and reflects airway inflammation. The anti-inflammatory effects of the leukotriene receptor antagonists and the markers of their activity continue to grow.
-
Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation
Journal of Allergy and Clinical Immunology, 2003Co-Authors: Anthony P Sampson, Emilio Pizzichini, Hans BisgaardAbstract:The understanding that Asthma Pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highly invasive (bronchial biopsy, bronchoalveolar lavage), moderately direct, and less invasive (indirect sputum, exhaled air, breath condensate) or indirect and least invasive (blood, urine). Several studies described in this review have implicated the cysteinyl leukotrienes (CysLTs) as inflammatory mediators in a wide range of diseases, implying that their biological activities reach far beyond acute bronchoconstriction, the activity traditionally ascribed to them. The validity of examining sputum for “biomarkers” has improved the understanding of Asthma Pathophysiology, optimization of Asthma treatment and management, and investigation of the relation between CysLTs and airway inflammation in Asthma. Nitric oxide is also a surrogate marker of Asthma and reflects airway inflammation. The anti-inflammatory effects of the leukotriene receptor antagonists and the markers of their activity continue to grow. (J Allergy Clin Immunol 2003;111:S49-61.)
Riccardina Tesse – One of the best experts on this subject based on the ideXlab platform.
-
Respiratory epithelial imbalances in Asthma Pathophysiology
Allergy and Asthma Proceedings, 2013Co-Authors: Fabio Cardinale, P. Giordano, I Chinellato, Riccardina TesseAbstract:The Pathophysiology of Asthma is complex and involves a number of factors including atopy and bronchial hyperreactivity. A strong body of evidence suggests that structural and functional respiratory epithelial alterations play a crucial role in both development and persistence of this condition. From the onset of symptoms the airways epithelium of Asthmatic patients seems to be altered and unable to repair. The interactions between the epithelium and the underlying mesenchyma, which are jointly referred to as the epithelial-mesenchymal trophic unit (EMTU), are thought to result in a self-sustaining damage of the airways and, ultimately, in a chronic inflammatory scenario. A better understanding of the relationship occurring across EMTU, environmental noxae, and factors of susceptibility to epithelial damage is likely to pave the way to future new preventive and therapeutic strategies for this condition.
Lawrence S. Schieken – One of the best experts on this subject based on the ideXlab platform.
-
Asthma Pathophysiology and the scientific rationale for combination therapy.
Allergy and asthma proceedings, 2002Co-Authors: Lawrence S. SchiekenAbstract:The clinical and scientific description of Asthma has been undergoing an evolution of continuous revision during the past 10 years. This disorder has been recognized as a complex entity with interplay between genetic, environmental, and allergenic factors resulting in a significant component of inflammation of the airway. Recent directions in therapy differ in taking either the broad-based antagonist or the specific mediator antagonist approach. This review highlights some of the scientific evidence of the operative pathophysiological events and reviews their applicability to the rationale for broad-based combination Asthma therapy.